163 related articles for article (PubMed ID: 38617010)
1. Biomarker Potential of
Ju Y; Zhu F; Fang B
Int J Med Sci; 2024; 21(5):921-936. PubMed ID: 38617010
[TBL] [Abstract][Full Text] [Related]
2. CYP4F12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via EMT pathway.
Jia W; Chen S; Wei R; Yang X; Zhang M; Qian Y; Liu H; Lei D
Sci Rep; 2023 Jul; 13(1):10956. PubMed ID: 37414830
[TBL] [Abstract][Full Text] [Related]
3. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
4. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
5. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
[TBL] [Abstract][Full Text] [Related]
6. FSCN1 is upregulated by SNAI2 and promotes epithelial to mesenchymal transition in head and neck squamous cell carcinoma.
Wang L; Jia Y; Jiang Z; Gao W; Wang B
Cell Biol Int; 2017 Aug; 41(8):833-841. PubMed ID: 28488774
[TBL] [Abstract][Full Text] [Related]
7. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
Huang J; Liang B; Wang T
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
[TBL] [Abstract][Full Text] [Related]
8. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
Front Immunol; 2022; 13():975847. PubMed ID: 36091055
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
Hu R; Lu M; She L
Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
[TBL] [Abstract][Full Text] [Related]
10.
Liu Z; Fang B; Cao J; Zhou Q; Zhu F; Fan L; Xue L; Huang C; Bo H
Bioengineered; 2022 May; 13(5):12141-12155. PubMed ID: 35575252
[TBL] [Abstract][Full Text] [Related]
11. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
[TBL] [Abstract][Full Text] [Related]
12. FDCSP Is an Immune-Associated Prognostic Biomarker in HPV-Positive Head and Neck Squamous Carcinoma.
Wu Q; Shao T; Huang G; Zheng Z; Jiang Y; Zeng W; Lv X
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291667
[No Abstract] [Full Text] [Related]
13. Exostoisns (EXT1/2) in Head and Neck Cancers: An In Silico Analysis and Clinical Correlates.
Wang Y; Huang Y; Zhu H; Guo Z; Cheng J; Zhang C; Zhong M
Int Dent J; 2024 Jun; 74(3):446-453. PubMed ID: 37989698
[TBL] [Abstract][Full Text] [Related]
14. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
15. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
[TBL] [Abstract][Full Text] [Related]
16. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of HOX genes promotes cell migration and proliferation in head and neck squamous cell carcinoma.
Aguiar GM; Ramão A; Plaça JR; Simões SC; Scaraboto NV; Freitas-Castro F; Cardoso C; Sousa JF; Silva WA
Tumour Biol; 2021; 43(1):263-278. PubMed ID: 34633333
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma.
Xiong HG; Li H; Xiao Y; Yang QC; Yang LL; Chen L; Bu LL; Zhang WF; Zhang JL; Sun ZJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):278. PubMed ID: 31238980
[TBL] [Abstract][Full Text] [Related]
19. Identification of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma (HNSC) for the Exploration of Immunotherapy and Prognosis.
Huang C; Liu J
Genet Res (Camb); 2022; 2022():6880760. PubMed ID: 36636556
[TBL] [Abstract][Full Text] [Related]
20. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
